SCHEMBL25344358

SCHEMBL25344358

Cn1ccc(Br)c(F)c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 2/20 0.37
BRD4 O60885 1/20 0.37
TAF1 P21675 1/20 0.37
BRPF1 P55201 1/20 0.37
CREBBP Q92793 1/20 0.37
CECR2 Q9BXF3 1/20 0.37
CRBN Q96SW2 1/20 0.34
CYP2C9 P11712 2/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
MAP2K1 Q02750 4/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
KDM6A O15550 1/20 0.32
KDM4A O75164 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM5C P41229 1/20 0.32
KDM2B Q8NHM5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2594416 0.77 BRD9 (0.39) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL21575044 0.76 BRD4 (0.38) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL29911927 0.76 BRD9 (0.38) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL19785547 0.74 BRD9 (0.37) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL31439950 0.74 ATAD2 (0.39) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL18259435 0.74 BRD9 (0.41) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL22990507 0.74 BRD4 (0.34) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL31364619 0.70 GAA (0.34) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL30097011 0.70 GAA (0.37) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL23706126 0.70 GAA (0.37) BRD9BRD4TAF1BRPF1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORP (US) 2025-09-11 US disclosed
CN-119212994-A Pyrazolopyrazine compounds as SHP2 inhibitors 建新公司 2024-12-27 CN disclosed
EP-4448526-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2024-10-23 EP disclosed
EP-4227307-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Genzyme Corporation (US) 2023-08-16 EP disclosed
WO-2023114954-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS PTPN5, PTPN2, PTPRJ BRD9 1150/4885BRD4 872/4885TAF1 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.